Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?

Literature DB >> 15604317

Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?

S von Haehling, S D Anker.

Abstract

Statins are being hailed as the new aspirin--but are they beneficial for patients with heart failure?

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2005 PMID： 15604317 PMCID： PMC1768667 DOI： 10.1136/hrt.2004.042515

Source DB: PubMed Journal: Heart ISSN： 1355-6037 Impact factor: 5.994

24 in total

1. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors: G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal: JAMA Date: 2001-04-04 Impact factor: 56.272

Review 2. The evolving role of statins in the management of atherosclerosis.

Authors: C J Vaughan; A M Gotto; C T Basson
Journal: J Am Coll Cardiol Date: 2000-01 Impact factor: 24.094

3. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury.

Authors: C Indolfi; A Cioppa; E Stabile; E Di Lorenzo; G Esposito; A Pisani; A Leccia; L Cavuto; A M Stingone; A Chieffo; C Capozzolo; M Chiariello
Journal: J Am Coll Cardiol Date: 2000-01 Impact factor: 24.094

4. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors: P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal: N Engl J Med Date: 2001-06-28 Impact factor: 91.245

5. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages.

Authors: K Pahan; F G Sheikh; A M Namboodiri; I Singh
Journal: J Clin Invest Date: 1997-12-01 Impact factor: 14.808

6. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.

Authors: D Tousoulis; C Antoniades; E Bosinakou; M Kotsopoulou; C Tsioufis; C Tentolouris; A Trikas; C Pitsavos; C Stefanadis
Journal: Heart Date: 2005-01 Impact factor: 5.994

7. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

Authors:
Journal: Lancet Date: 1999-08-07 Impact factor: 79.321

8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors:
Journal: N Engl J Med Date: 1998-11-05 Impact factor: 91.245

9. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.

Authors: C Bustos; M A Hernández-Presa; M Ortego; J Tuñón; L Ortega; F Pérez; C Díaz; G Hernández; J Egido
Journal: J Am Coll Cardiol Date: 1998-12 Impact factor: 24.094

10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245

6 in total

Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?

1. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Review 2. The evolving role of statins in the management of atherosclerosis.

3. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury.

4. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

5. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages.

6. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.

7. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

9. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.

10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

1. Heart failure: statins for all?

Review 2. [Percutaneous aortic valve replacement - pro].

Review 3. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review.

Review 4. Nutritional and anti-inflammatory interventions in chronic heart failure.

Review 5. Should a statin be prescribed to every patient with heart failure?

Review 6. Myocardial protection in man--from research concept to clinical practice.